Pigmented Lesion Assay (PLA)
Commercial- Indications
- Melanoma detection
Company intelligence / Profile preview
Ignite Biosciences developed a proprietary computational proteomics platform aimed at identifying proteins via their binding properties. Patent filings suggest applications in blood-based diagnostics for health monitoring and early disease detection. The company operated largely in stealth mode before being renamed/succeeded by Nautilus Biotechnology in 2020. No clinical results were published prior to transition to Nautilus Biotechnology[2][5].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ignite Biosciences.